{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:10:40Z","timestamp":1793052640205,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1053\/j.seminhematol.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T11:23:14Z","timestamp":1717154594000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Contemporary radiation therapy use in Hodgkin lymphoma"],"prefix":"10.1053","volume":"61","author":[{"given":"Omran","family":"Saifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0001","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jama.1902.62480030024001h","article-title":"Cases of sarcoma and of Hodgkin's disease treated by exposures to X-rays\u2014a preliminary report","volume":"XXXVIII","author":"WA","year":"1902","journal-title":"J Am Med Assoc"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0002","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0003","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2008.10.048","article-title":"Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma","volume":"75","author":"Dhakal","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ijrobp.2021.06.030","article-title":"Clinical outcomes confirm conjecture: modern radiation therapy reduces the risk of late toxicity in survivors of Hodgkin lymphoma","volume":"111","author":"Milgrom","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.006_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.16232","article-title":"No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy","volume":"188","author":"Lagerl\u00f6f","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0006","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2020.02.642","article-title":"Long-term outcomes in 10-year survivors of early-stage Hodgkin lymphoma","volume":"107","author":"Bates","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.05.006_bib0007","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1200\/JCO.21.02407","article-title":"Limited, but not eliminated, excess long-term morbidity in stage I-IIA Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine and limited-field radiotherapy","volume":"40","author":"Lagerl\u00f6f","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.05.006_bib0008","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMe2211587","article-title":"Are we too reliant on radiation therapy for children with Hodgkin's lymphoma?","volume":"387","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0009","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/OP.23.00640","article-title":"Re-examining trials of radiotherapy omission: when less is not always more","volume":"20","author":"Sanford","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.05.006_bib0010","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.05.006_bib0011","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.05.006_bib0012","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1200\/JCO.23.01386","article-title":"Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma","volume":"42","author":"Neppelenbroek","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.05.006_bib0013","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0014","doi-asserted-by":"crossref","first-page":"332","DOI":"10.18632\/oncotarget.23013","article-title":"Low dose radiation prevents doxorubicin-induced cardiotoxicity","volume":"9","author":"Jiang","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0016","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2015.64.6588","article-title":"Minimizing cardiac risks with contemporary radiation therapy for Hodgkin lymphoma","volume":"34","author":"Maraldo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.05.006_bib0017","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.05.006_bib0018","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin Lymphoma","volume":"42","author":"Federico","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.05.006_bib0020","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.05.006_bib0021","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.05.006_bib0022","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.18.01799","article-title":"Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID Study","volume":"37","author":"Barrington","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.006_bib0024","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.22.00947","article-title":"Positron emission tomography-adapted therapy in bulky stage I\/II classic Hodgkin lymphoma: CALGB 50801 (Alliance)","volume":"41","author":"LaCasce","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.05.006_bib0025","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.05.006_bib0026","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0027","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1053\/j.seminhematol.2024.05.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.05.006_bib0029","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1053\/j.seminhematol.2024.05.006_bib0030","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.05.006_bib0031","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.05.006_bib0032","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0033","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0034","first-page":"467","article-title":"Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial","volume":"20","author":"Ferm\u00e9","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.006_bib0035","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0036","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0037","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0959-8049(98)00304-9","article-title":"Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group","volume":"35","author":"Tsang","year":"1999","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0038","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0039","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.bmt.1701325","article-title":"Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors","volume":"22","author":"Lancet","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.05.006_bib0041","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.05.006_bib0042","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.006_bib0043","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.HS9.0000843704.08384.3e","article-title":"S203: abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma: pre-planned interim analysis of the international GHSG phase II Aern trial","volume":"6","author":"Br\u00f6ckelmann","year":"2022","journal-title":"HemaSphere"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0044","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1667\/RR15048.1","article-title":"Complete local and abscopal responses from a combination of radiation and nivolumab in refractory Hodgkin's lymphoma","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijrobp.2020.02.636","article-title":"Abscopal regressions of lymphoma after involved-site radiation therapy confirmed by positron emission tomography","volume":"108","author":"MacManus","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2024.05.006_bib0046","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.05.006_bib0047","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.05.006_bib0048","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.05.006_bib0049","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0051","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2007.07.003","article-title":"Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?","volume":"85","author":"Girinsky","year":"2007","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0052","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.09.007","article-title":"Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma","volume":"80","author":"Paumier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0053","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2015.02.008","article-title":"Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma","volume":"92","author":"Hoppe","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0054","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14338\/IJPT-19-00077.1","article-title":"Irradiating residual disease to 30 Gy with proton therapy in pediatric mediastinal Hodgkin lymphoma","volume":"6","author":"Hoppe","year":"2020","journal-title":"Int J Part Ther"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.05.006_bib0055","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.05.006_bib0056","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0057","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaoncol.2015.4794","article-title":"Radiation therapy for Hodgkin lymphoma\u2014can it be administered more safely if necessary?","volume":"2","author":"Straus","year":"2016","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.05.006_bib0058","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0059","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ijrobp.2021.10.152","article-title":"Patterns of initial relapse from a phase 3 study of response-based therapy for high-risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group","volume":"112","author":"Parikh","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.05.006_bib0060","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.2022016098","article-title":"Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis","volume":"140","author":"Parekh","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.05.006_bib0061","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.006_bib0062","unstructured":"National Comprehensive Cancer Guidelines: Hodgkin lymphoma. https:\/\/www.nccn.org\/professionals\/physician)_gls\/pdf\/hodgkins.pdf. accessed 03.11.2023."},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0063","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2014.01.041","article-title":"Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma","volume":"89","author":"Filippi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0064","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2011.11.008","article-title":"Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement","volume":"84","author":"Lu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.05.006_bib0065","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3109\/10428194.2014.975802","article-title":"Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma","volume":"56","author":"Sachsman","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0066","doi-asserted-by":"crossref","first-page":"343","DOI":"10.14338\/IJPT.14.00001.1","article-title":"Advancing the therapeutic index in stage III\/IV pediatric Hodgkin lymphoma with proton therapy","volume":"1","author":"Holtzman","year":"2014","journal-title":"Int J Particle Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.006_bib0067","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijrobp.2010.05.035","article-title":"Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage Hodgkin lymphoma in female patients","volume":"81","author":"Weber","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0068","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0069","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.006_bib0070","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ijrobp.2014.04.029","article-title":"Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study","volume":"89","author":"Hoppe","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.006_bib0071","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.prro.2019.09.015","article-title":"The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era","volume":"10","author":"Hoppe","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.05.006_bib0072","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.006_bib0073","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.seminoncol.2014.10.001","article-title":"Special cases for proton beam radiotherapy: re-irradiation, lymphoma, and breast cancer","volume":"41","author":"Plastaras","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.006_bib0074","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2022.10.003","article-title":"Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: a PTCOG Lymphoma Subcommittee report and recommendations","volume":"177","author":"Patel","year":"2022","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.006_bib0075","doi-asserted-by":"crossref","first-page":"492","DOI":"10.14338\/IJPT-17-00012","article-title":"Comparing breath hold and free breathing during intensity-modulated radiation therapy and proton therapy in patients with mediastinal Hodgkin lymphoma","volume":"3","author":"Hoppe","year":"2017","journal-title":"Int J Part Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.006_bib0076","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3109\/10428194.2010.493250","article-title":"Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma","volume":"51","author":"Hoppe","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.006_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00010.1","article-title":"Reducing heart dose with protons and cardiac substructure sparing for mediastinal lymphoma treatment","volume":"7","author":"Taparra","year":"2020","journal-title":"Int J Part Ther"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.05.006_bib0078","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T13:04:47Z","timestamp":1726837487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0037196324000702"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary radiation therapy use in Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}